Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Long-Term Safety and Tolerability Study of Depot Buprenorphine (RBP-6000) in Treatment-Seeking Subjects With Opioid Use Disorder

Next Previous
Search
Trial Profile

An Open-Label, Long-Term Safety and Tolerability Study of Depot Buprenorphine (RBP-6000) in Treatment-Seeking Subjects With Opioid Use Disorder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buprenorphine (Primary) ; Buprenorphine/naloxone (Primary)
  • Indications Opioid-related disorders
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Indivior

Most Recent Events

  • 01 May 2022 Results investigating diverse array of outcomes for individuals with OUD at an average of 4.2 years post clinical trial participation from NCT023579011; NCT025100142; NCT02896296 & NCT03604861 were published in the Drug and Alcohol Dependence.
  • 02 Nov 2020 Results of population pharmacokinetics from (NCT01738503, NCT02357901 and NCT02510014) published in the Clinical Pharmacokinetics
  • 16 Apr 2020 Results presented in an Indivior Media Release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top